Stock likely to rise on EPS beat and strong BRINSUPRI launch metrics. Monitor ENCORE sNDA submission in H2 2026 and TPIP data in Q3 2026 for further catalysts.
INSM drugs
INSM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $105.00entry
- T+1 · 6mo ago −3.48%α −4.31% · $101.35
- T+5 · 6mo ago +12.37%α +10.87% · $117.99
- T+20 · 6mo ago −1.09%α −4.22% · $103.86
- T+60 · 4mo ago −6.24%α −10.07% · $98.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Insmed reported Q1 2026 total revenue of $306.0M (up 230% YoY, driven by BRINSUPRI launch) and a net loss of $163.6M ($0.76 per share), beating consensus EPS of -$0.90. The company reiterated 2026 BRINSUPRI revenue guidance of at least $1B and ARIKAYCE guidance of $450-470M, and highlighted positive ENCORE Phase 3b results. The stronger-than-expected launch trajectory and EPS beat are positive catalysts.
Key Financial Metrics
Key Facts
- Total Q1 2026 revenue: $306.0M vs $92.8M in Q1 2025 (+230% YoY)
- BRINSUPRI revenue: $207.9M (+44% vs Q4 2025)
- ARIKAYCE revenue: $98.1M (+6% vs Q1 2025)
- Net loss: $163.6M ($0.76 per share) vs $256.6M ($1.42) in Q1 2025
- EPS beat consensus of -$0.90 by 15.6%
- Reiterated 2026 BRINSUPRI revenue ≥$1B and ARIKAYCE $450-470M
- Phase 3b ENCORE study met all primary and secondary endpoints
- Cash, cash equivalents, and marketable securities: $1.2B as of March 31, 2026
Financial Impact
EPS beat by $0.14 (15.6%) on consensus -$0.90; revenue beat unknown due to lack of consensus
Risk Factors
- Still unprofitable with operating loss of $153.3M in Q1 2026
- Cash burn expected to continue, though path to cash flow positive in 2027
- Dependence on BRINSUPRI launch momentum and label expansion for ARIKAYCE
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-019430 |
| Document: ef20072589_ex99-2.htm | 0001140361-26-019430 |
| Document: ef20072589_8k.htm | 0001140361-26-019430 |
| Document: 0001140361-26-019430-index-headers.html | 0001140361-26-019430 |
| Document: 0001140361-26-019430-index.html | 0001140361-26-019430 |
| Document: 0001140361-26-019430.txt | 0001140361-26-019430 |
| 8-K Data (Synthetic) | 0001140361-26-019430 |
Track record
24 reports on INSM
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $122.88 +10.12% settles Nov 27
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $122.88 +30.67% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $122.88 +28.44% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $122.88 +18.35% ▲ +8.43% +10.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $122.88 −1.76% ▼ −4.06% −4.19% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $126.33 to $129.41 Now $122.88 −2.73% ▲ +2.44% +4.19% vs SPY
- Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $122.88 −7.30% ▼ −4.43% −5.03% vs SPY
- Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $122.88 +14.93% ▲ +17.63% +14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers